Apogee Therapeutics (APGE) News Today $36.62 -1.17 (-3.10%) Closing price 04:00 PM EasternExtended Trading$36.63 +0.01 (+0.03%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Affinity Asset Advisors LLC Has $43.01 Million Stake in Apogee Therapeutics Inc. $APGEAugust 28 at 9:02 AM | marketbeat.comApogee Therapeutics Inc. $APGE Shares Sold by Vanguard Group Inc.August 26 at 3:04 AM | marketbeat.comWellington Management Group LLP Raises Holdings in Apogee Therapeutics Inc. $APGEAugust 23, 2025 | marketbeat.comWedbush Reduces Earnings Estimates for Apogee TherapeuticsAugust 16, 2025 | marketbeat.comApogee Therapeutics (APGE) Is Up 5.9% After Strong APG777 Phase 2 Data and Accelerated PlansAugust 15, 2025 | finance.yahoo.comApogee Therapeutics Faces Supply Chain Risks Amid Geopolitical Tensions and Regulatory ChallengesAugust 12, 2025 | msn.comApogee Therapeutics (NASDAQ:APGE) Posts Earnings ResultsAugust 12, 2025 | marketbeat.comApogee Therapeutics' (APGE) Outperform Rating Reiterated at WedbushAugust 12, 2025 | marketbeat.comApogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comCarl Dambkowski Sells 2,725 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) StockAugust 10, 2025 | marketbeat.comXTX Topco Ltd Raises Stock Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)August 6, 2025 | marketbeat.comApogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic ...August 5, 2025 | theglobeandmail.comApogee Therapeutics (APGE) Projected to Post Quarterly Earnings on MondayAugust 5, 2025 | marketbeat.comApogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Buy" from AnalystsAugust 5, 2025 | marketbeat.comTD Asset Management Inc Reduces Stock Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)August 3, 2025 | marketbeat.comJefferies Financial Group Inc. Sells 465,701 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE)August 2, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)July 28, 2025 | marketbeat.comJefferies Sticks to Its Buy Rating for Apogee Therapeutics (APGE)July 27, 2025 | theglobeandmail.comApogee Therapeutics Reports Positive Phase 2 Trial ResultsJuly 27, 2025 | theglobeandmail.comVictory Capital Management Inc. Grows Stock Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)July 25, 2025 | marketbeat.comBank of New York Mellon Corp Has $8 Million Stake in Apogee Therapeutics Inc. (NASDAQ:APGE)July 23, 2025 | marketbeat.comJennison Associates LLC Sells 18,634 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE)July 21, 2025 | marketbeat.comBTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy RatingJuly 16, 2025 | finance.yahoo.comCanaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE)July 14, 2025 | msn.comStifel reiterates Buy rating on Apogee Therapeutics stock amid positive ...July 11, 2025 | investing.comApogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Buy" from BrokeragesJuly 11, 2025 | marketbeat.comApogee Therapeutics Shares Surge After Promising Eczema Drug Trial ResultsJuly 9, 2025 | msn.comApogee falls after results from atopic dermatitis trialJuly 8, 2025 | msn.comApogee Therapeutics Inc. (APGE) Stock Price Today - WSJJuly 8, 2025 | wsj.comApogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress InvestorsJuly 8, 2025 | msn.comApogee Therapeutics (NASDAQ:APGE) Stock Price Down 7.6% - Time to Sell?July 8, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Apogee Therapeutics (NASDAQ:APGE)July 7, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Given New $115.00 Price Target at BTIG ResearchJuly 7, 2025 | marketbeat.comApogee Therapeutics reports positive Phase 2 results for atopic dermatitis drugJuly 7, 2025 | proactiveinvestors.comApogee Therapeutics reports positive Phase 2 results for atopic dermatitis drugJuly 7, 2025 | proactiveinvestors.comApogee Therapeutics (NASDAQ:APGE) Sees Strong Trading Volume - Should You Buy?July 7, 2025 | marketbeat.comApogee Therapeutics Sees Unusually Large Options Volume (NASDAQ:APGE)July 7, 2025 | marketbeat.comApogee stock soars after positive atopic dermatitis trial dataJuly 7, 2025 | au.investing.comApogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic DermatitisJuly 7, 2025 | globenewswire.comApogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025July 6, 2025 | globenewswire.comApogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in AsthmaJuly 6, 2025 | msn.comInsider Selling: Apogee Therapeutics Inc. (NASDAQ:APGE) Insider Sells 10,090 Shares of StockJuly 4, 2025 | insidertrades.comApogee Therapeutics Inc. (NASDAQ:APGE) Insider Sells $454,958.10 in StockJuly 3, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Shares Up 6.9% - Here's What HappenedJuly 3, 2025 | marketbeat.comGuggenheim Reaffirms Buy Rating for Apogee Therapeutics (NASDAQ:APGE)July 2, 2025 | marketbeat.comNotable Friday Option Activity: APGE, SATS, M - NasdaqJune 29, 2025 | nasdaq.comApogee Therapeutics Inc News (APGE) - Investing.comJune 24, 2025 | investing.comApogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Recommendation of "Buy" by BrokeragesJune 16, 2025 | marketbeat.comApogee Therapeutics (NASDAQ:APGE) Shares Up 5.3% - What's Next?June 13, 2025 | marketbeat.comCarl Dambkowski Sells 2,725 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) StockJune 6, 2025 | marketbeat.com Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APGE Media Mentions By Week APGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APGE News Sentiment▼1.790.99▲Average Medical News Sentiment APGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APGE Articles This Week▼55▲APGE Articles Average Week Get the Latest News and Ratings for APGE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Apogee Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RVMD News Today RYTM News Today RNA News Today NUVL News Today AXSM News Today CRSP News Today ABVX News Today MRUS News Today CYTK News Today VKTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APGE) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access